FHM type 2 (FHM2), associated with ATP1A2 mutations, disrupts astrocytic Na+/K+-ATPase function and may present with seizures, encephalopathy, or prolonged neurological deficits. This evidence concerns the gene CACNA1A and Encephalopathy.